, constrained by inhibitor solubility at the low--inhibitor--affinity end and TAMRA--TPX2 1--43 -Aurora A K d at the high--inhibitor--affinity end. The ideal working dynamic range range was determined to be between mM and 100 nM. Ramachandran outliers (%) 
Supplementary Figure 2: HTS hits retested on FA assay in presence of ATP--site blocking JNJ--7706621

Supplementary Methods
Preparation of human Aurora--A Kinase Expression Plasmids
Human Aurora--A kinase was produced using λPP co--expression method described for mouse Aurora--A 3 . Enterbacterial phage lambda phosphatase (λPP) gene (GenBank ID: 270346) was amplified by PCR using cloning primers 1 and 2 that included XhoI and HindIII restriction sites as well as the Shine--Dalgarno ribosome binding sequence. Digested and purified PCR product was ligated into pBAT4 and pHAT4 expression plasmids 4 linearized with XhoI and HindIII restriction endonucleases resulting in plasmids pBAT4--λPP and pHAT4--λPP, respectively.
Human Aurora--A kinase gene fragment encoding residues 126--390 was amplified by PCR using cloning primers 3 and 4, digested with NcoI and XhoI restriction endonucleases and ligated into the NcoI and XhoI linearised pBAT4--λPP plasmid upstream the λPP gene resulting in Aurora--A expression construct termed AurA G--126--390 .
AurA G--126--390 T287A mutant was generated by PCR overlap extension method using cloning primers 3 and 4 and mutation primers 5 and 6.
Another Aurora--A kinase expression construct termed AurA GSMGS--126--391 was cloned into pBAT4--λPP vector using cloning primers 7 and 8. AurA GSMGS--126--391 expression construct encoded human Aurora--A kinase residues 126--391 and carried a TEV--cleavable N--terminal 6xHis--tag.
The Aurora--A kinase expression construct used for FA assay termed AurA 123--403 , was produced differently. The Human Aurora--A kinase gene fragment encoding residues 123--403 was amplified by PCR using cloning primers 9 and 10. It was then digested by ClaI and XhoI restriction endonucleases and ligated into the ClaI and XhoI linearised pBAD--HisA vector (Invitrogen), prepared in SCS110 E.coli to prevent methylation of ClaI site. AurA 123--403 expression construct encoded an N--terminal region carrying 6xHis--tag as well as EK recognition site (sequence: MGGSHHHHHHGMASMTGGQQM GRDLYDDDDKDR) in addition to Aurora--A kinase residues 123--403.
Primer Sequence
Generation of stable cell line, maintenance and selection
HeLa FlpIn TREx cell line (a kind gift from Professor Stephen Taylor, University of Manchester) was used to generate stable cell line. The cells were maintained in DMEM medium (with GlutaMax, Invitrogen) with 10% FCS and Zeocin (50 µg ml --1 ) and blasticidin (4 µg ml --1 ).
The mCherry--TPX2 1--43 construct was prepared by cloning mCherry and TPX2 1--43 sequences into pCDNA3.1 (--) vector. The mCherry gene was amplified by PCR using primers 11 and 12, and cloned into pCDNA3.1 (--) vector by XbaI and XhoI restriction endonucleases. The TPX2 1--43 gene fragment was constructed by annealing designed oligomers (13, 14, 15 and 16) followed by 5'end phosphorylation by T4 polynucleotide kinase. The TPX2 1--43 sequence was cloned into the pCDNA3.1 (--) vector at EcoRI and BamHI sites. mCherry--TPX2 1--43 was sub--cloned from the previously generated pCDNA3.1 (--) construct (see above) into pcDNA5/FRT/TO vector at PmeI site. The clones generated were tested by colony PCR and the directionality of insert was established using EcoRI / XbaI restriction digestion. A construct with desired orientation were verified by sequencing and used for generating the stable cell line.
The mCherry--TPX2 construct was co--transfected with pOG44 (Invitrogen) using JETPrime reagent following manufacturer's instructions. Hygromycin (200 µg ml --1 ) and blasticidin resistant cells were selected, pooled and expanded. The cells were always maintained on antibiotic containing medium.
Pooled clones were sorted by a cell sorter (BD Biosciences) into 96--well plate with one cell per well. The medium was changed regularly and when cells had expanded these were replica plated and tested for the expression of mCherry--TPX2 by high content microscopy as described below. A clone with high expression and low background was selected, expanded and used for further experiments.
Preparation of Supplementary Video
The video depicts the transition between the Aurora A crystals structure containing ATP (AurA G--126--390 _T287A_ATP (5DRD)) and crystals structure of Aurora A with bound ATP and AurkinA (AurkinA_AurA G--126--390 _T287A_ATP (5DOS)). The video was prepared by 'morphing' from the apo structure to the AurkinA complex and back, using UCSF chimera package 5 .
Chemical Synthesis of AURKA--TPX2 inhibitor analogues
General procedure: Pfitzinger reaction According to the procedure described by Giardina et al. 6 , isatin (1.0 eq), acetophenone (1.2 eq) and KOH (3.0 eq) were dissolved in EtOH. The reaction mixture was heated under reflux for 48--72 h and the solvent was removed under reduced pressure. The residue was dissolved in H 2 O and washed with equal volume of Et 2 O twice. The aqueous layer was cooled to 0 °C, acidified to pH 2 with (conc.) HCl and the precipitate was collected as a crude product, which was then triturated or recrystallised.
methyl 2--(2--phenylquinoline--4--carboxamido)benzoate
Methyl anthranilate (0.30 mL, 2.41 mmol), cinchophen (500 mg, 2.01 mmol) and DIPEA (0.70 mL, 4.01 mmol) were added to oven--dried round--bottomed flask containing dry EtOAc (10 mL). The mixture was cooled to 0 °C and T3P (50% in EtOAc, 1.8 mL, 3.01 mmol) was added dropwise and the reaction mixture was stirred at 0 °C for 30 min. The mixture was allowed to warm up to RT and after overnight stirring, the reaction was quenched by addition of H 2 O. The mixture was diluted with EtOAc and the organic layer was washed with (sat.) NaHCO 3 , brine, dried (MgSO 4 ), filtered and the solvent was removed under reduced pressure. The crude product was purified by flash column 
2--(2--phenylquinoline--4--carboxamido)benzoic acid (1)
Using the general procedure, the methyl ester 11 (100 mg, 0.26 mmol) was hydrolysed to yield pure product as white solid (86 mg, 84%). 
2--(4--hydroxyphenyl)quinoline--4--carboxylic acid (24)
Using the general procedure, isatin (1.00 g, 6.8 mmol), 4--hydroxyacetophenone (1.111 g, 8.16 mmol) and KOH (1.144 g, 20.4 mmol) were combined yielding the crude product, which was subsequently recrystallised from EtOH to yield the pure product (125 mg, 13% 
6--chloro--2--phenylquinoline--4--carboxylic acid (25)
Using the general procedure, 5--chloroisatin (1.00 g, 5.51 mmol), acetophenone (0.77 g, 6.61 mmol) and KOH (0.93 g, 16.53 mmol) were combined to yield the crude product, which was subsequently recrystallised from EtOH to yield the pure product (190 mg, 13% 
2--(3--fluorophenyl)quinoline--4--carboxylic acid (26)
Using the general procedure, isatin (500 mg, 3.4 mmol), 3--fluoroacetophenone (0.50 mL, 4.08 mmol) and KOH (572 mg, 10.2 mmol) were combined yielding the crude product, which was subsequently recrystallised from EtOH to yield the pure product (322 mg, 35% 
6--chloro--2--(3--fluorophenyl)quinoline--4--carboxylic acid (27)
Using the general procedure, 5--chloroisatin (500 mg, 2.75 mmol), 3--fluoroacetophenone (0.42 mL, 3.44 mmol) and KOH (464 mg, 8.27 mmol) were combined yielding the crude product, which was subsequently recrystallised from EtOH to yield the pure product (65 mg, 8% 
6--bromo--2--(3--fluorophenyl)quinoline--4--carboxylic acid (28)
Using the general procedure, 5--bromoisatin (500 mg, 2.2 mmol), 3--fluoroacetophenone (0.33 mL, 2.7 mmol) and KOH (370 mg, 6.6 mmol) were combined yielding the crude product, which was subsequently recrystallised from 80 % EtOH in H 2 O to yield the pure product (35 mg, 5% 
2--(3--bromophenyl)--6--chloroquinoline--4--carboxylic acid (AA29)
N
2--(3--bromophenyl)quinoline--4--carboxylic acid (AA30)
Using the general procedure, isatin (500 mg, 3.4 mmol), 3--bromoacetophenone (0.46 mL, 3.45 mmol) and KOH (506 mg, 9.0 mmol) were combined yielding the crude product, which was subsequently recrystallised from EtOH to yield the pure product (425 mg, 38%). IR (solid) ν max 3200--2600 (O--H 
6--chloro--2--(pyridin--3--yl)quinoline--4--carboxylic acid (31)
Using the general procedure, 5--chloroisatin (500 mg, 2.75 mmol), 3--acetylpyridine (0.35 mL, 3.45 mmol) and KOH (464 mg, 8.27 mmol) were combined yielding the crude product, which was subsequently recrystallised from acetone to yield the pure product (61 mg, 12%). IR (solid) ν max 3100--2800 (O--H 
2--(3,5--difluorophenyl)quinoline--4--carboxylic acid (32)
Using the general procedure, isatin (147 mg, 1.0 mmol), 3,5--difluoroacetophenone (188 mg, 1.2 mmol) and KOH (168 mg, 3.0 mmol) were combined yielding the crude product, which was subsequently recrystallised from acetone to yield the pure product (157 mg, 55%). 
IR
2--(3--(trifluoromethyl)phenyl)quinoline--4--carboxylic acid (34)
Using the general procedure, isatin (250 mg, 1.70 mmol), 3--(trifluoromethyl)--fluoroacetophenone (0.26 mL, 2.03 mmol) and KOH (286 mg, 5.1 mmol) were combined yielding the crude product, which was subsequently recrystallised from 90% EtOH in H 2 O to yield the pure product (85 mg, 16% 
methoxy--N--methyl--3--(trifluoromethyl)benzamide (45)
To an oven--dried round--bottomed flask was added Et 3 N (3 mL) and N,O--dimethylhydroxyamine hydrochloride (731 mg, 7.5 mmol) in dry DCM (5 mL). Solution of 3--(trifluoromethyl)benzoyl chloride (0.75 mL, 5.0 mmol) in dry DCM (3 mL) was added dropwise into ice--cooled reaction mixture which was allowed to warm up to RT and stirred for 18 h. The reaction was quenched by addition of H20 (10 mL). The organic layer was washed with (sat.) NaHCO 3 , brine, dried (MgSO 4 ), filtered and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography (100% DCM) to yield the product (1.046 g, 90% Mg filings (344 mg, 14.15 mmol) in dry Et 2 O (10 mL) were added to an oven--dried round--bottomed flask. Benzyl bromide (1.12 mL, 9.43 mmol) was added dropwise into the solution at RT and the reaction mixture was heated under reflux for 1h. After it was allowed to cool to RT, the solution was added dropwise to ice--cold solution of 45 (1100 mg, 4.72 mmol) dissolved in dry Et 2 O in an oven--dried round--bottomed flask. The reaction mixture was allowed to warm up to RT and stirred overnight. The mixture was cooled on ice and HCl (3N) was added carefully to quench the reaction. The organic layer was washed with brine, dried (MgSO 4 ), filtered and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography (20% Hexane in DCM) to yield the desired product (943 mg, 87% 
1--methyl--3--phenylisoquinoline (48)
2--phenylacetophenone (2.96 g, 15.1 mmol) was dissolved in dry acetonitrile (125 mL) contained in oven--dried round--bottomed flask. Phosphoryl chloride (9.0 mL, 90.6 mmol) was added dropwise at RT and the solution was refluxed for 72 h. The solvent was removed under reduced pressure, the solid residue was redissolved in H 2 O, basified with NaOH (2N) and extracted with DCM. The organic layer was washed with brine, dried (MgSO 4 ), filtered and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography (3% MeOH in DCM) to yield colourless oil (882 mg, 27% 
1--methyl--3--(3--(trifluoromethyl)phenyl)isoquinoline (49)
46 (900 mg, 3.41 mmol) was dissolved in dry acetonitrile (25 mL) contained in oven--dried round--bottomed flask. Phosphoryl chloride (1.27 mL, 13.63 mmol) was added dropwise at RT and the solution was refluxed for 72 h. The solvent was removed under reduced pressure, the solid residue was redissolved in H 2 O, basified with NaOH (2N) and extracted with DCM. The organic layer was washed with brine, dried (Na 2 SO 4 ), filtered and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography (50% DCM / 50% Hexane) to yield colourless oil (268 mg, 27% 
3--phenylisoquinoline--1--carboxylic acid (50)
48 (380 mg, 1.6 mmol), N--Bromosuccinimide (850 mg, 4.8 mmol) and benzoyl peroxide (30 mg, 0.12 mmol) were dissolved in CCl 4 (10 mL) and heated under reflux for 20 h. The insoluble material was filtered off through Celite, the filtrate was washed with NaHCO 3 (5 %) and the solvent was removed under reduced pressure to yield orange oil that was utilized without further purification. The oil residue was dissolved in a mixture of THF (4 mL) and EtOH (8 mL) and heated to reflux. Solution of AgNO 3 (1.09 g, 6.40 mmol) in H 2 O (2 mL) was added, the reaction mixture was heated under reflux for 1 h and the insoluble material was removed on Celite while still hot. The filtrate was evaporated to dryness and utilised without further purification. 
